A share price of Rocket Pharmaceuticals Inc [RCKT] is currently trading at $30.74, up 3.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The RCKT shares have gain 7.33% over the last week, with a monthly amount glided 8.81%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress. In a post published today on Yahoo Finance, Advancing leading pipeline of six disclosed programs across AAV cardiovascular and LV hematology portfolios; all milestones remain on track for 2024.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on October 24, 2023, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $65. Previously, Morgan Stanley started tracking the stock with Overweight rating on February 01, 2023, and set its price target to $45. On November 08, 2022, Canaccord Genuity initiated with a Buy rating and assigned a price target of $53 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $35 on November 01, 2022. Raymond James initiated its recommendation with a Outperform and recommended $22 as its price target on July 08, 2022. In a note dated March 02, 2021, Stifel initiated an Buy rating and provided a target price of $64 on this stock.
Rocket Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $14.89 and $32.53. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $30.74 at the most recent close of the market. An investor can expect a potential return of 67.53% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.67 points at the first support level, and at 28.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.64, and for the 2nd resistance point, it is at 32.54.
Rocket Pharmaceuticals Inc [RCKT] reported earnings per share of -$0.64 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.79/share, meaning a difference of $0.15 and a surprise factor of 19.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.75 per share as compared to estimates of -$0.81 per share, a difference of $0.06 representing a surprise of 7.40%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rocket Pharmaceuticals Inc [NASDAQ:RCKT] is 13.35. On the other hand, the Quick Ratio is 13.35, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Shah Gaurav, CEO, that happened on Feb 16 when 20272.0 shares were sold., Patel Kinnari completed a deal on Feb 16 to sell 7132.0 shares. Meanwhile, General Counsel Wilson Martin sold 3576.0 shares on Feb 16.
